Trial Profile

The combination of aripiprazole and selective serotonin reuptake inhibitor (SSRI) antidepressants [citalopram, escitalopram, sertraline] in the acute treatment of psychotic major depression: Efficacy and tolerability.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Aug 2012 Actual patient number changed from 35 to 16 as reported by ClinicalTrials.gov.
14 Mar 2012 Primary endpoint identified as clinical response as reported by ClinicalTrials.gov.
14 Mar 2012 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com